RU2012134065A - Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления - Google Patents
Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления Download PDFInfo
- Publication number
- RU2012134065A RU2012134065A RU2012134065/15A RU2012134065A RU2012134065A RU 2012134065 A RU2012134065 A RU 2012134065A RU 2012134065/15 A RU2012134065/15 A RU 2012134065/15A RU 2012134065 A RU2012134065 A RU 2012134065A RU 2012134065 A RU2012134065 A RU 2012134065A
- Authority
- RU
- Russia
- Prior art keywords
- intraocular pressure
- weight
- benzimidazole
- bromo
- ylamino
- Prior art date
Links
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 26
- 230000004410 intraocular pressure Effects 0.000 claims abstract 19
- 239000000203 mixture Substances 0.000 claims abstract 15
- JHOJNZYPXCAPKL-UHFFFAOYSA-N 4-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-1h-benzimidazol-5-amine Chemical compound C1=CC=2NC=NC=2C(Br)=C1N=C1NCCN1 JHOJNZYPXCAPKL-UHFFFAOYSA-N 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 239000003755 preservative agent Substances 0.000 claims abstract 6
- 230000002335 preservative effect Effects 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000006184 cosolvent Substances 0.000 claims abstract 2
- 230000001839 systemic circulation Effects 0.000 claims abstract 2
- 238000011200 topical administration Methods 0.000 claims abstract 2
- 239000005022 packaging material Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 210000001742 aqueous humor Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29691210P | 2010-01-21 | 2010-01-21 | |
| US61/296,912 | 2010-01-21 | ||
| PCT/US2011/022001 WO2011091225A2 (en) | 2010-01-21 | 2011-01-21 | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012134065A true RU2012134065A (ru) | 2014-02-27 |
Family
ID=44169074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134065/15A RU2012134065A (ru) | 2010-01-21 | 2011-01-21 | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9889088B2 (enExample) |
| EP (1) | EP2525793B1 (enExample) |
| JP (3) | JP2013518051A (enExample) |
| KR (1) | KR20120125305A (enExample) |
| CN (1) | CN102770135A (enExample) |
| AU (1) | AU2011207301A1 (enExample) |
| BR (1) | BR112012018154A2 (enExample) |
| CA (1) | CA2787573A1 (enExample) |
| CL (1) | CL2012002038A1 (enExample) |
| CO (1) | CO6592108A2 (enExample) |
| IL (1) | IL221030A0 (enExample) |
| MX (1) | MX2012008516A (enExample) |
| RU (1) | RU2012134065A (enExample) |
| SG (1) | SG182637A1 (enExample) |
| TW (1) | TW201141477A (enExample) |
| WO (1) | WO2011091225A2 (enExample) |
| ZA (1) | ZA201205470B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130046003A1 (en) * | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2013016072A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| BR112014001501A2 (pt) * | 2011-07-22 | 2017-02-14 | Allergan Inc | moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho |
| WO2014159576A1 (en) * | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| TWI699205B (zh) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | 用於預防或治療青光眼之藥物療法 |
| WO2019004080A1 (ja) | 2017-06-27 | 2019-01-03 | 国立大学法人東京大学 | 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法 |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| PT4236932T (pt) * | 2020-11-02 | 2026-02-23 | Visus Therapeutics Inc | Composto degradante num medicamento |
| WO2023086878A1 (en) * | 2021-11-10 | 2023-05-19 | Visus Therapeutics, Inc. | Carbachol formulations to enhance anti-presbyopia effects |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| AU704972B2 (en) * | 1994-08-04 | 1999-05-13 | H. Lundbeck A/S | Novel benzimidazole derivatives |
| US6495583B1 (en) * | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| CA2603044A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Alpha-2 adrenergic agonists for the treatment of pain |
| CA2641501A1 (en) | 2006-02-06 | 2007-08-16 | Nicox S.A. | Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
-
2011
- 2011-01-21 MX MX2012008516A patent/MX2012008516A/es unknown
- 2011-01-21 JP JP2012550140A patent/JP2013518051A/ja active Pending
- 2011-01-21 KR KR1020127021719A patent/KR20120125305A/ko not_active Withdrawn
- 2011-01-21 AU AU2011207301A patent/AU2011207301A1/en not_active Abandoned
- 2011-01-21 CN CN2011800111530A patent/CN102770135A/zh active Pending
- 2011-01-21 TW TW100102411A patent/TW201141477A/zh unknown
- 2011-01-21 EP EP11702342.4A patent/EP2525793B1/en not_active Not-in-force
- 2011-01-21 RU RU2012134065/15A patent/RU2012134065A/ru unknown
- 2011-01-21 BR BR112012018154A patent/BR112012018154A2/pt not_active IP Right Cessation
- 2011-01-21 WO PCT/US2011/022001 patent/WO2011091225A2/en not_active Ceased
- 2011-01-21 CA CA2787573A patent/CA2787573A1/en not_active Abandoned
- 2011-01-21 US US13/010,958 patent/US9889088B2/en not_active Expired - Fee Related
- 2011-01-21 SG SG2012053815A patent/SG182637A1/en unknown
-
2012
- 2012-07-19 IL IL221030A patent/IL221030A0/en unknown
- 2012-07-20 ZA ZA2012/05470A patent/ZA201205470B/en unknown
- 2012-07-20 CL CL2012002038A patent/CL2012002038A1/es unknown
- 2012-08-17 CO CO12140238A patent/CO6592108A2/es not_active Application Discontinuation
-
2015
- 2015-10-28 JP JP2015211447A patent/JP2016026206A/ja active Pending
-
2017
- 2017-04-26 JP JP2017086952A patent/JP6466504B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SG182637A1 (en) | 2012-08-30 |
| ZA201205470B (en) | 2013-05-29 |
| CA2787573A1 (en) | 2011-07-28 |
| WO2011091225A3 (en) | 2012-05-18 |
| JP6466504B2 (ja) | 2019-02-06 |
| CO6592108A2 (es) | 2013-01-02 |
| JP2013518051A (ja) | 2013-05-20 |
| KR20120125305A (ko) | 2012-11-14 |
| US9889088B2 (en) | 2018-02-13 |
| JP2017125074A (ja) | 2017-07-20 |
| BR112012018154A2 (pt) | 2016-04-05 |
| AU2011207301A1 (en) | 2012-08-09 |
| TW201141477A (en) | 2011-12-01 |
| EP2525793A2 (en) | 2012-11-28 |
| WO2011091225A2 (en) | 2011-07-28 |
| IL221030A0 (en) | 2012-09-24 |
| US20110178145A1 (en) | 2011-07-21 |
| CN102770135A (zh) | 2012-11-07 |
| JP2016026206A (ja) | 2016-02-12 |
| MX2012008516A (es) | 2012-10-15 |
| EP2525793B1 (en) | 2018-09-05 |
| CL2012002038A1 (es) | 2012-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518051A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| MX2016009666A (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| JP2016539921A5 (enExample) | ||
| JP2017214429A5 (enExample) | ||
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| JP7787129B2 (ja) | 眼科組成物 | |
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| JP5872131B2 (ja) | 抗真菌医薬組成物 | |
| MX337364B (es) | Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol. | |
| RU2013110003A (ru) | Комбинация соединений для лечения или предотвращения кожных заболеваний | |
| BR112012018154A2 (pt) | agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular | |
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| RU2013111633A (ru) | Стабильная жидкая фармацевтическая композиция комплекса 3-(2,2,2-триметилгидразиний) пропионат-2-этил-6-метил-3-гидроксипиридина дисукцината, обладающая антигипоксическим, антиоксидантным и адаптогенным действием | |
| JP2016537364A5 (enExample) | ||
| WO2015100348A8 (en) | Keloid reduction using topical allantoin | |
| JP2014530847A5 (enExample) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| WO2014011949A3 (en) | Neuroprotective cb2 receptor agonists | |
| JP6333023B2 (ja) | 水性医薬組成物 | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| AR083893A1 (es) | Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente | |
| JP6785797B2 (ja) | リポ酸および粘膜模倣ポリマーを含んでなる眼科用組成物 |